CD274 and chordoma: As a potential alternative clinical option for PD-L1–positive tumors, we interrogated the sensitivity of chordoma cell lines to lysis by human NK cells that have been genetically engineered to express the high-affinity CD16 receptor, endoplasmic reticulum–retained IL2, and a CAR-specific against PD-L1 (41, 42).